NKGN (NKGen Biotech) Short-Term Debt : $19.70 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Short-Term Debt?

NKGen Biotech's Short-Term Debt for the quarter that ended in Sep. 2024 was $19.70 Mil.

NKGen Biotech's quarterly Short-Term Debt increased from Mar. 2024 ($11.57 Mil) to Jun. 2024 ($17.28 Mil) and increased from Jun. 2024 ($17.28 Mil) to Sep. 2024 ($19.70 Mil).

NKGen Biotech's annual Short-Term Debt declined from Dec. 2021 ($51.15 Mil) to Dec. 2022 ($11.66 Mil) and declined from Dec. 2022 ($11.66 Mil) to Dec. 2023 ($9.99 Mil).

NKGen Biotech Short-Term Debt Historical Data

The historical data trend for NKGen Biotech's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Short-Term Debt Chart

NKGen Biotech Annual Data

Trend

Dec21

Dec22

Dec23

Short-Term Debt

51.15

11.66

9.99

NKGen Biotech Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt	Get a 7-Day Free Trial					5.23	9.99	11.57	17.28	19.70

NKGen Biotech Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

NKGen Biotech Short-Term Debt Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (OTCPK:NKGN) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

3001 Daimler Street, Santa Ana, CA, USA, 92705

Website

https://www.nkgenbiotech.com

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.